To corroborate the xenograft data, we examined FGF-2 expression in tumor specimens obtained from treatment-naive GIST patients (n = 20), and patients received IM-based therapy for at least 12–16 months (n = 10). The gene discussed is FGF2; the disease is neoplasm.